Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 151 AL 165

The road to restoring neural circuits for the treatment of Alzheimer's disease

Canter RG, Penney J, Tsai LH.

Nature. 2016 Nov 10;539(7628):187-196. doi: 10.1038/nature20412.

The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions

Fargo KN, Carrillo MC, Weiner MW, Potter WZ, Khachaturian Z.

Alzheimers Dement. 2016 Nov;12(11):1113-1115. doi: 10.1016/j.jalz.2016.10.001.

Pharmacological Effects of Active Components of Chinese Herbal Medicine in the Treatment of Alzheimer's Disease: A Review

Wang ZY, Liu JG, Li H, Yang HM.

Am J Chin Med. 2016;44(8):1525-1541. doi: 10.1142/S0192415X16500853. Epub 2016 Nov 16.

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR, Wischik CM.

Lancet. 2016 Dec 10;388(10062):2873-2884. doi: 10.1016/S0140-6736(16)31275-2. Epub 2016 Nov 16.

Promise of new Alzheimer's drug is dashed after lack of evidence

Hawkes N.

BMJ. 2016 Nov 24;355:i6362. doi: 10.1136/bmj.i6362.

Sixty seconds on . . . solanezumab

Hawkes N.

BMJ. 2016 Nov 29;355:i6389. doi: 10.1136/bmj.i6389.

Development and Structural Modification of BACE1 Inhibitors

Gu T, Wu WY, Dong ZX, Yu SP, Sun Y, Zhong Y, Lu YT, Li NG.

Molecules. 2016 Dec 22;22(1):4. doi: 10.3390/molecules22010004.

Solanezumab and the amyloid hypothesis for Alzheimer's disease

Le Couteur DG, Hunter S, Brayne C.

BMJ. 2016 Dec 29;355:i6771. doi: 10.1136/bmj.i6771.

Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies

Rygiel K.

Indian J Pharmacol. 2016 Nov-Dec;48(6):629-636. doi: 10.4103/0253-7613.194867.

Amyloid-beta immunotherapy: the hope for Alzheimer disease?

Barrera-Ocampo A, Lopera F.

Colomb Med (Cali). 2016 Dec 30;47(4):203-212.

Non-Pharmacological Approaches to the Prevention and Treatment of Alzheimer's Disease with Respect to the Rising Treatment Costs

Klimova B, Maresova P, Kuca K.

Curr Alzheimer Res. 2016;13(11):1249-1258. doi: 10.2174/1567205013666151116142302.

The Human Alzheimer Disease Project: Answering the Call

DeKosky ST, Growdon JH.

JAMA Neurol. 2016 Apr;73(4):373-4. doi: 10.1001/jamaneurol.2015.4512.

Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings

Heßmann P, Seeberg G, Reese JP, Dams J, Baum E, Müller MJ, Dodel R, Balzer-Geldsetzer M.

J Alzheimers Dis. 2016;51(2):545-61. doi: 10.3233/JAD-150835.

Effects of Exercise on Cognition: The Finnish Alzheimer Disease Exercise Trial: A Randomized, Controlled Trial

Öhman H, Savikko N, Strandberg TE, Kautiainen H, Raivio MM, Laakkonen ML, Tilvis R, Pitkälä KH.

J Am Geriatr Soc. 2016 Apr;64(4):731-8. doi: 10.1111/jgs.14059. Epub 2016 Apr 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias